

Claims

1. The use of *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, in the
5 manufacture of a medicament for use in the treatment of cancer in a warm blooded animal such as man.
2. The use of the compound according to claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the reduction of abnormal proliferation
10 in a cancerous cell or inducing differentiation of a cancerous cell in a warm blooded animal such as man.
3. The use of the compound according to claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in inducing apoptosis in a cancerous cell
15 in a warm blooded animal such as man.
4. The use of the compound according to claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use as an anti-angiogenic and vascular targeting agent in blood vessels a cancerous cell in a warm blooded animal such as man.
20
5. The use of the compound according to claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use as an anti-angiogenic agent in a warm blooded animal such as man.
- 25 6. The use according to claim 1 wherein the cancer is oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, ewings tumour, neuroblastoma, Kaposi sarcoma, ovarian cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, lung cancer - non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric cancer, head and neck cancer, renal cancer lymphoma and leukaemia.
30
7. The use according to claim 1 wherein the cancer is prostate cancer.

8. The use according to claim 1 wherein the cancer is SCLC, NSCLC, colorectal cancer, ovarian cancer and / or breast cancer.
9. The use according to claim 1 wherein the cancer is bladder cancer, oesophageal
5 cancer, gastric cancer, melanoma, cervical cancer and / or renal cancer.
10. The use according to claim 1 wherein the cancer is endometrial, liver, stomach, thyroid, rectal and / or brain cancer.
- 10 11. The use according to claim 1 wherein the cancer is SCLC.
12. The use according to claim 1 wherein the cancer is NSCLC.
13. The use according to claim 1 wherein the cancer is colorectal cancer.
- 15 14. The use according to claim 1 wherein the cancer is ovarian cancer.
15. The use according to claim 1 wherein the cancer is breast cancer.
- 20 16. The use according to any one of claims 1 and 6-15 wherein the cancer is in a metastatic state.
17. The use according to any one of claims 1 and 6-15 wherein the cancer is in a non-metastatic state.
- 25 18. The use according to any one of claims 1 and 6-15 wherein the cancer is renal, thyroid, lung, breast or prostate cancer that is producing bone metastases.
19. The use of the compound according to claim 1, or a pharmaceutically acceptable salt
30 thereof, in the manufacture of a medicament for use as an inhibitor of bone metastases and an inhibitor of invasion in a warm blooded animal such as man.

20. The use of the compound according to claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use as an inhibitor of bone metastases in a warm blooded animal such as man.

5 21. The use of the compound according to claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the prevention of bone metastases in a warm blooded animal such as man.

22. The use of the compound according to claim 1, or a pharmaceutically acceptable salt
10 thereof, in the manufacture of a medicament for use in the treatment of bone metastases in a warm blooded animal such as man.

23. The use of *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide), or a pharmaceutically acceptable salt thereof, in the
15 manufacture of a medicament for use in the prevention or treatment of pain in a warm blooded animal such as man.

24. The use of *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, in the
20 manufacture of a medicament for use in the prevention or treatment of pain associated with elevated endothelin-1 production in a warm blooded animal such as man.

25. The use of *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, in the
25 manufacture of a medicament for use in the prevention or treatment of pain associated with stimulation of the ET_A receptor in a warm blooded animal such as man.